Connective tissue diseases mostly belong to autoimmune diseases, which include various diseases such as systemic lupus erythematosus, rheumatoid arthritis, dry syndrome, polymyositis/dermatomyositis, leukoaraiosis, and systemic sclerosis. Autoimmune diseases are a group of diseases in which the main pathogenesis is tissue and organ damage and corresponding dysfunction caused by the immune response to self-antigens due to the weakened immune tolerance of the organism. Currently, the treatment of autoimmune diseases is based on glucocorticoids and immunosuppressants, but some patients still respond poorly to conventional drug therapy and their disease progresses and worsens.
Mesenchymal stem cell therapy for connective tissue diseases is a novel treatment method, and according to the results of previous clinical studies, it is still effective for some patients who are not satisfied with the results of conventional treatment. In addition, it should be noted that this program treatment is a research clinical trial treatment, not a mature technology (the Ministry of Health has not yet conducted a unified issuance of the relevant access certificate), but by the day the technology is mature, you may have already missed the best time for treatment. The Ministry of Health is taking a relatively strict management of all stem cell therapy programs.
The starting point of this is to prevent immature technologies from being carried out by units that are not qualified to do so, for the purpose of charging a profit. However, without clinical trial studies, it will never be possible to achieve clinical promotion in the future. It is also not good for the patients to reject “mesenchymal stem cell” treatment. Our rheumatology team in Jiangsu has completed more than 200 cases, which are generally safe and bring a little hope for some refractory cases. But any treatment method is not a “myth”, and MSC treatment is the same, but only as a supplement to the traditional treatment.
Mesenchymal stem cells are the most promising type of stem cells for clinical application, and they have the ability to differentiate into many kinds of cells, as well as the ability to support hematopoiesis and regulate immune function. Through their secretion of soluble cytokines in patients, they improve the microenvironment of damaged tissues, inhibit abnormally activated immune cells, and reduce the formation of autoantibodies to achieve the purpose of controlling the condition of connective tissue diseases, but their exact mechanism needs to be further explored.
There are various sources of MSCs, and bone marrow-derived MSCs are inconvenient for clinical application due to their low content and ethical issues. Umbilical cord or placenta-derived MSCs have biological properties similar to bone marrow MSCs, and also have the following advantages.
(1) No ethical issues;
(2) Abundant source;
(3) lower probability of infectious diseases.
The MSCs we use are derived from umbilical cord tissue and are cultured and expanded with the most advanced international technology.
If you participate in the clinical study of this program, you will receive 1 or 2 sessions of MSC treatment free of charge. Other related examination fees and hospitalization costs during the treatment will be borne by you. With the established protocol of MSC treatment, your condition may improve for a longer period of time, thus reducing the dosage of drugs such as hormones and other immunosuppressive drugs, helping to reduce the adverse effects caused by these drugs, improving your quality of life and reducing the cost of treatment in the future.
The MSC infusion process is generally safe, but MSC therapy, like other clinical treatment techniques, may involve certain risks while treating the disease, especially due to abnormalities in the patient’s condition, or due to individual differences, or due to some other unpredictable factors that make it unrealistic and beyond the current state of science to completely avoid these risks in the current field of medical technology. The current level of science is not possible.
Although, in our accumulated clinical practice to date, we have not seen any serious adverse reactions. However, we still want to warn you of the possibility of some side effects, including but not limited to the following.
①Mild fever, malaise, dizziness and other reactions;
②Infection due to immunosuppressive effect;
(3) The effect of the treatment is not obvious, the improvement of the disease is different from your expectation, or even the treatment is ineffective.
For your safety, the doctor will monitor these situations thoroughly, and if abnormal reactions occur during the treatment, we will provide you with comprehensive treatment for your condition.
However, to date, there are still many patients who wish to receive umbilical cord mesenchymal stem cell transplantation treatment, and we have worked hard to obtain a small number of free treatment slots for a variety of diseases such as systemic lupus erythematosus, rheumatoid arthritis, dry syndrome, polymyositis/dermatomyositis, leukodystrophy, and systemic sclerosis. If you need, you can contact us.
Friendly reminder: people with the following conditions cannot receive MSC treatment.
1.History of serious drug allergy or allergic person;
2.People who have serious infection or combined with malignant tumor;
3.Heart function grade 3 to 4 or end-stage renal insufficiency;
4.Persons with mental abnormalities and severe cognitive impairment;
5.Serum HIV and other pathogenic pathogens are positive;
6.Patients with severe coagulation disorders;
7. Those who have participated in other clinical studies within 3 months before enrollment;
8.Patients who are pregnant;
9.The investigator believes that there are other reasons for not being included in this study.